User:Phtawiki/sandbox
| Submission declined on 25 May 2025 by Timtrent (talk). This submission is not adequately supported by reliable sources. Reliable sources are required so that information can be verified. If you need help with referencing, please see Referencing for beginners and Citing sources. This draft's references do not show that the subject qualifies for a Wikipedia article. In summary, the draft needs to
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
| Submission declined on 25 May 2025 by ToadetteEdit (talk). This submission is not adequately supported by reliable sources. Reliable sources are required so that information can be verified. If you need help with referencing, please see Referencing for beginners and Citing sources. This submission's references do not show that the subject qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published, reliable, secondary sources that are independent of the subject (see the guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see technical help and learn about mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia. Declined by ToadetteEdit 8 days ago. | |
Comment: You have almost exclusively used primary spources.For a living person we have a high standard of referencing. Every substantive fact you assert, especially one that is susceptible to potential challenge, requires a citation with a reference that is about them, and is independent of them, in multiple secondary sources which are WP:RS, and is significant coverage. Please also see WP:PRIMARY which details the limited permitted usage of primary sources and WP:SELFPUB which has clear limitations on self published sources. Providing sufficient references, ideally one per fact cited, that meet these tough criteria is likely to make this draft a clear acceptance (0.9 probability). Lack of them or an inability to find them is likely to mean that the person is not suitable for inclusion, certainly today. 🇵🇸🇺🇦 FiddleTimtrent FaddleTalk to me 🇺🇦🇵🇸 10:03, 25 May 2025 (UTC)
- Comment: Should the title be 'Luigi Martini', 'Gino Martini', or 'Luigi G. Martini'? The sources seem to use all of these, but it's not clear which one the person actually goes by (per WP:COMMONNAME). DoubleGrazing (talk) 09:34, 25 May 2025 (UTC)
Professor Luigi Martini is CEO, Precision Health Technologies Accelerator Birmingham Health Innovation Campus.[1] With extensive experience in oncology, rare diseases and infectious diseases, and drug development, Professor Luigi Martini also brings expertise in policy development and external advocacy to his appointment in Birmingham. An experienced academic, Professor Luigi Martini has also held senior development and advisory positions within industry, including GSK, Roche and SmithKline Beecham.
Previously Professor Luigi Martini was a Professor of Pharmaceutical Innovation at King's College London[2] and Chief Scientific Officer of The Start Up Funding Club, which invested over £3 Million in over 30 Start Ups. Professor Martini was the UK's first and only Industrial Pharmacist teaching practitioner, bridging the gap between Industry and Academia.[3][4]
Awards & Achievements
[edit]Professor Luigi Martini is an award-winning pharmaceutical professional with extensive experience across Industry, Academia and Professional Leadership Bodies. He has a diverse background in oncology, rare diseases, infectious disease, drug development, medical affairs, policy development and government/external advocacy. Additionally, he has significant expertise working in Emerging Markets, particularly in the Middle East (Saudi Arabia, UAE, Bahrain)
Professor Martini is the inventor of 'DiffCORE[5]' a groundbreaking drug delivery technology. This innovation led to the development and commercialisation of Lamictal (lamotrigine) XR, which was launched in July 2009 for the treatment of partial seizures. DiffCORE[5] represents the first new oral drug delivery platform to be introduced in the pharmaceutical sector in over a decade.
References
[edit]- ^ "Meet the team".
- ^ "Gino Martini". King's College London. Retrieved 2025-05-19.
- ^ Augsburger, Larry L.; Hoag, Stephen W. (2017-10-30). Pharmaceutical Dosage Forms: Capsules. CRC Press. ISBN 978-1-351-62039-0.
- ^ "Luigi G Martini takes up post as RPS chief scientist". The Pharmaceutical Journal. 2018-01-03. Retrieved 2025-05-19.
- ^ a b Tompson, Debra; Whitaker, Mark; Pan, Rennan; Johnson, Geoffrey; Fuller, Teresa; Zann, Vanessa; McKenzie, Litza; Abbott-Banner, Kathy; Hawkins, Simon; Powell, Marcy (January 25, 2022). "Development of a Once-Daily Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772 using DiffCORE Technology". Pharmaceutical Research. 39 (1): 153–165. doi:10.1007/s11095-021-03124-7. PMC 8837545. PMID 34988780.